5CD3

Structure of immature VRC01-class antibody DRVIA7

Summary for 5CD3

• Entry DOI: 10.2210/pdb5cd3/pdb
• Related: 5CD5
• Descriptor: DRVIA7 Heavy Chain, DRVIA7 Light Chain (2 entities in total)
• Functional Keywords: vrc01, hiv-1, cd4 binding site, gp120, immune system
• Biological source: Homo sapiens; More
• Total number of polymer chains: 8
• Total formula weight: 189023.61

Authors

Kong, L.,Wilson, I.A. (deposition date: 2015-07-02, release date: 2016-04-06, Last modification date: 2024-11-13)

Primary citation

Kong, L.,Ju, B.,Chen, Y.,He, L.,Ren, L.,Liu, J.,Hong, K.,Su, B.,Wang, Z.,Ozorowski, G.,Ji, X.,Hua, Y.,Chen, Y.,Deller, M.C.,Hao, Y.,Feng, Y.,Garces, F.,Wilson, R.,Dai, K.,O'Dell, S.,McKee, K.,Mascola, J.R.,Ward, A.B.,Wyatt, R.T.,Li, Y.,Wilson, I.A.,Zhu, J.,Shao, Y.
Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.
Immunity, 44:939-950, 2016

PubMed Abstract: VRC01-class antibodies neutralize diverse HIV-1 strains by targeting the conserved CD4-binding site. Despite extensive investigations, crucial events in the early stage of VRC01 development remain elusive. We demonstrated how VRC01-class antibodies emerged in a Chinese donor by antigen-specific single B cell sorting, structural and functional studies, and longitudinal antibody and virus repertoire analyses. A monoclonal antibody DRVIA7 with modest neutralizing breadth was isolated that displayed a subset of VRC01 signatures. X-ray and EM structures revealed a VRC01-like angle of approach, but less favorable interactions between the DRVIA7 light-chain CDR1 and the N terminus with N276 and V5 glycans of gp120. Although the DRVIA7 lineage was unable to acquire broad neutralization, longitudinal analysis revealed a repertoire-encoded VRC01 light-chain CDR3 signature and VRC01-like neutralizing heavy-chain precursors that rapidly matured within 2 years. Thus, light chain accommodation of the glycan shield should be taken into account in vaccine design targeting this conserved site of vulnerability.

PubMed: 27067056
DOI: 10.1016/j.immuni.2016.03.006

Experimental method

X-RAY DIFFRACTION (2.9 Å)